An antihyperkinetic action by the serotonin 1A-receptor agonist osemozotan co-administrated with psychostimulants or the non-stimulant atomoxetine in mice

DOI Web Site 被引用文献1件 参考文献35件
  • Tsuchida Rie
    Laboratory of Molecular Neuropharmacology, Graduate School of Pharmaceutical Sciences, Osaka University, Japan
  • Kubo Masahiro
    Laboratory of Molecular Neuropharmacology, Graduate School of Pharmaceutical Sciences, Osaka University, Japan
  • Kuroda Mariko
    Laboratory of Molecular Neuropharmacology, Graduate School of Pharmaceutical Sciences, Osaka University, Japan
  • Shibasaki Yasuhiro
    Laboratory of Molecular Neuropharmacology, Graduate School of Pharmaceutical Sciences, Osaka University, Japan
  • Shintani Norihito
    Laboratory of Molecular Neuropharmacology, Graduate School of Pharmaceutical Sciences, Osaka University, Japan
  • Abe Michikazu
    Pharmacology Department IV, Mitsubishi Tanabe Pharma Corporation, Japan
  • Köves Katalin
    Department of Human Morphology and Developmental Biology, Faculty of Medicine, Semmelweis University, Hungary
  • Hashimoto Hitoshi
    Laboratory of Molecular Neuropharmacology, Graduate School of Pharmaceutical Sciences, Osaka University, Japan Center for Child Mental Development, Graduate School of Medicine, Osaka University, Japan
  • Baba Akemichi
    Laboratory of Molecular Neuropharmacology, Graduate School of Pharmaceutical Sciences, Osaka University, Japan

書誌事項

タイトル別名
  • An Antihyperkinetic Action by the Serotonin 1A-Receptor Agonist Osemozotan Co-administered With Psychostimulants or the Non-stimulant Atomoxetine in Mice

この論文をさがす

抄録

It has been demonstrated that treatment of hyperactive mice with psychostimulants produced a calming effect depending on serotonergic neurotransmission. Our previous study also showed that hyperactivity in mice lacking pituitary adenylate cyclase–activating polypeptide (PACAP) was ameliorated by amphetamine in a serotonin (5-HT)1A-dependent manner and that amphetamine calmed wild-type mice given the 5-HT1A agonist 8-OH-DPAT. Here, we examined if 5-HT1A–mediated pathways can be a determinant of the action of other psychostimulants as well as the non-stimulant atomoxetine by examining locomotor activity in mice co-administered with the 5-HT1A agonist osemozotan. Co-administration of osemozotan with either methamphetamine or amphetamine was not only antihyperkinetic, but also decreased locomotion to below basal levels. In contrast, osemozotan just nullified methylphenidate-induced hyperactivity. The non-stimulant atomoxetine did not induce hyperactivity, but co-administration of atomoxetine with osemozotan produced a calming effect. The adjunctive effect of osemozotan added to the psychostimulants was blocked by the 5-HT1A antagonist WAY-100635 at a low dose (0.1 mg/kg), suggesting the involvement of a presynaptic 5-HT1A–mediated mechanism. However, WAY-100635 (up to 1 mg/kg) did not block the effect of atomoxetine plus osemozotan. The present results may provide insights into the therapeutic mechanisms of the psychostimulants and atomoxetine for hyperkinetic disorders.<br>

収録刊行物

被引用文献 (1)*注記

もっと見る

参考文献 (35)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ